Cytori Therapeutics (CYTX)
Cytori Therapeutics Market Cap: 126.29M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYTX Market Cap Rankings
| Overall | 26th percentile | 3425 of 4649 |
| Sector | 35th percentile | 341 of 525 in Healthcare |
| Industry | 39th percentile | 99 of 163 in Biotechnology |
CYTX Market Cap Range, Past 5 Years
| Minimum | 58.62M | Mar 2009 |
| Maximum | 406.33M | Mar 2011 |
| Average | 170.81M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these CYTX related companies
CYTX News
$CYTX - Cell therapy industry update on public co.s in Cell Stem Cell - http://stks.co/3mq0
about 17 days ago by CytoriIR
about 17 days ago by CytoriIR
EBR: Watchlist/worksheet/4 Trading Ideas: That was $CYTX not $ATHX
about 17 days ago by TheEquitiesRoom
about 17 days ago by TheEquitiesRoom
$CYTX wow 13% up and climbing - news in the wind? Hoping for a #HALT on #BO news
about 18 days ago by RickPalmer907
about 18 days ago by RickPalmer907
More details in $CYTX May 2012 shareholder letter: http://stks.co/3kdo
about 19 days ago by CytoriIR
about 19 days ago by CytoriIR
Just posted: $CYTX first quarter earnings results: http://stks.co/3kdd
about 19 days ago by CytoriIR
about 19 days ago by CytoriIR
$CYTX Think a partnership with major pharmaceutical announcement during earnings call? I do! Think $TVA
about 19 days ago by RickPalmer907
about 19 days ago by RickPalmer907
$CYTX - What could be the true intrinsic value of Cytori? Deliberations and prerequisits for 10x our wildest dreams- http://stks.co/3iKW
about 21 days ago by cytxinvestor
about 21 days ago by cytxinvestor
Questions for $CYTX conf call on May 9? Post here or email directly at cytori.com">mmccormick@cytori.com
about 21 days ago by CytoriIR
about 21 days ago by CytoriIR
@adamfeuerstein Mind if I ask your opinion on $CYTX? Should I be looking in rear view mirror - or the road ahead?
about 26 days ago by RickPalmer907
about 26 days ago by RickPalmer907
$CYTX Been on this and waiting for he trend to continue up past $3 soon
about 27 days ago by RickPalmer907
about 27 days ago by RickPalmer907
$CYTX anyone else noticing this move on the charts for the past week?
about 33 days ago by RickPalmer907
about 33 days ago by RickPalmer907
Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results
Mar 08, 4:05PM Marketwire
Mar 08, 4:05PM Marketwire
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing
Feb 15, 8:20AM Marketwire
Feb 15, 8:20AM Marketwire
FDA Grants Cytori Therapeutics (CYTX) Investigational Device Exemption Approval to Begin ATHENA Trial
Jan 30, 8:05AM Street Insider
Jan 30, 8:05AM Street Insider
Cytori Therapeutics (CYTX) Reports APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Funct
Jan 24, 7:17AM Street Insider
Jan 24, 7:17AM Street Insider
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution(R) System
Dec 19, 8:00AM Marketwire
Dec 19, 8:00AM Marketwire
Cytori (CYTX) Announces Celution One System is Granted European CE Mark Approval
Nov 30, 8:21AM Street Insider
Nov 30, 8:21AM Street Insider
Advanced Cell Technology and Cytori Therapeutics Gain Support as Geron Changes Strategy
Nov 28, 8:16AM Marketwire
Nov 28, 8:16AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTX | 2.18 | +0.04 | +1.87% | 126.29M |
| CYTR | 3.45 | +0.20 | +6.15% | 73.17M |
| CYTK | 0.93 | +0.02 | +2.20% | 71.03M |
| CVBK | 0.86 | -0.08 | -8.51% | 2.262M |
| CVA | 15.79 | -0.03 | -0.19% | 2.149B |
| CV | 35.13 | -0.02 | -0.06% | 473.55M |
| CUZ | 7.42 | +0.09 | +1.23% | 772.72M |
| CUTR | 6.94 | -0.20 | -2.80% | 96.81M |
| CUT | 16.04 | +0.04 | +0.24% | |
| CURE | 39.59 | +0.00 | +0.00% |
